Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

Teva Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Parkinson's Disease

Treatments: Drug: rasagiline mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00203138

TVP - 1012/233

Details and patient eligibility

About

Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be monitored.

Enrollment: 306 patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who completed evaluations of week 52 of the TVP 1012/232 protocol, where continued rasagiline therapy is warranted, in the opinion of the principal investigator

Exclusion criteria

• Patients having suffered adverse effects that were probably drug-related in the TVP-1012/232 study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)